http://rdf.ncbi.nlm.nih.gov/pubchem/patent/BR-112022003704-A2

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_966a6c1f382ec9bcb5e3839dfd73e5b8
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D498-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5383
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D498-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5383
filingDate 2020-09-07-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2ffda8530530077b544f04daa05cf821
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e683dc0f6e8eb81653e79bb2c09d605b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c9cae043b81bb7fa59a3088366ae1b25
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0fd9b2687786236e766ea0d520e43d8f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ff1862b3e4d14d5df2937cd435b8c727
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_08aa9a0ba83c3b64e64d5fb66a7eaaad
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fcdd1f1b419b833bf05999d8f6dc08a2
publicationDate 2022-05-24-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber BR-112022003704-A2
titleOfInvention 4,4a,5,7,8,8a-hexapyrido[4,3-b][1,4]oxazin-3-one compounds as magl inhibitors
abstract 4,4a,5,7,8,8a-hexapyrido[4,3-b][1,4]oxazin-3-one compounds as magl inhibitors. the present invention relates to novel heterocyclic compounds of general formula (i), wherein a, b, l, x, r1, r2, r3 and r4 are as described herein, compositions including the compounds, manufacturing processes of the compounds and methods of using the compounds as inhibitors of monoacylglycerol lipase (magl).
priorityDate 2019-09-09-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID11343
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID64195
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419792816
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID29254
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID23945
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID21873527

Total number of triples: 35.